SEC Form 10-Q filed by Philip Morris International Inc
$PM
Medicinal Chemicals and Botanical Products
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2024 | Buy → Hold | Argus | |
| 2/13/2024 | Sell → Hold | Societe Generale | |
| 1/23/2024 | $105.00 → $86.50 | Buy → Sell | UBS |
| 11/16/2023 | $95.00 | Neutral | Redburn Atlantic |
| 6/20/2023 | $109.00 → $117.00 | Neutral → Buy | Citigroup |
| 4/14/2023 | $114.00 | Buy | Stifel |
| 3/30/2023 | $109.00 → $116.00 | Neutral → Overweight | JP Morgan |
| 3/1/2023 | $106.00 → $116.00 | Neutral → Buy | UBS |
Argus downgraded Philip Morris International from Buy to Hold
Societe Generale upgraded Philip Morris International from Sell to Hold
UBS downgraded Philip Morris International from Buy to Sell and set a new price target of $86.50 from $105.00 previously
Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 third-quarter and first nine-months results.1 "In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share," said Jacek Olczak, Chief Executive Officer. "This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance." "As a result of our strong year-to-date delivery, we
CCAA Plan Includes PMI's Canadian Affiliate RBH, Deconsolidated Since 2019; If RBH Reconsolidated, Expected to be Incremental to Key PMI Financial Metrics Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantiall
Vectura Fertin Pharma, Inc., an affiliate of Philip Morris International Inc. (PMI) (NYSE:PM), today announces the sale of its subsidiary Vectura Group Ltd. (Vectura) to Molex Asia Holdings Ltd., and the establishment of master service agreements to develop Vectura Fertin Pharma's inhaled therapeutics proprietary pipeline. Vectura will be operated by Phillips Medisize, a Molex company. The sale includes upfront cash consideration of GBP 150 million, subject to customary purchase price adjustments, and potential deferred payments of up to GBP 148 million. The transaction is subject to customary closing conditions, including regulatory approval. "In line with our ambitions, Vectura has enabl
JP Morgan analyst Jared Dinges maintains Philip Morris Intl (NYSE:PM) with a Overweight and raises the price target from $110 to $125.
Investors with a lot of money to spend have taken a bearish stance on Philip Morris Intl (NYSE:PM). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PM, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 9 uncommon options trades for Philip Morris Intl. This isn't normal. The overall sentiment of these big-money traders is split between 22% bullish and 44%, bearish. Out of all of
B of A Securities analyst Lisa Lewandowski maintains Philip Morris Intl (NYSE:PM) with a Buy and raises the price target from $110 to $118.
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex
Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what
In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002
8-K - Philip Morris International Inc. (0001413329) (Filer)
FWP - Philip Morris International Inc. (0001413329) (Subject)
10-Q - Philip Morris International Inc. (0001413329) (Filer)
Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 third-quarter and first nine-months results.1 "In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share," said Jacek Olczak, Chief Executive Officer. "This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance." "As a result of our strong year-to-date delivery, we
CCAA Plan Includes PMI's Canadian Affiliate RBH, Deconsolidated Since 2019; If RBH Reconsolidated, Expected to be Incremental to Key PMI Financial Metrics Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantiall
Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast at www.pmi.com/2024Q3earnings on Tuesday, October 22, 2024, at 9:00 a.m. ET, to discuss its 2024 third-quarter and first nine-months results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The webcast recording and the slides and script will be